First, how relevant is PARP-1’s activity across cell/tissue types in SARS-CoV-2 pathogenesis and second, can miRNA-mediated regulation of PARP-1 be exploited as a therapeutic target to prevent SARS-CoV-2 infection to mitigate COVID-19 pathological outcomes? The gene discussed is PARP1; the disease is COVID-19.